Step Pharma Set To Leap Into Clinic With CTPS1 Inhibitor
French Biotech Raises €35m
After a fresh cash injection, Step is ready to take STP938 for the treatment of T-cell blood cancers into Phase I trials in February.
You may also be interested in...
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).
Following last year's licensing deal with Precision Biosciences and the acquisition of Prevail Therapeutics, Eli Lilly is expanding its gene therapy efforts by backing Jaguar, a start-up staffed by former AveXis bosses.
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.